Table 3

Average maximal CCA-IMT and average annual maximal CCA-IMT progression in people with and without diabetes

Average max CCA-IMT (mm)Average annual max CCA-IMT progression (mm/year)
CohortDiabetes, mean (SD)No diabetes, mean (SD)Difference, mean (SE)&Diabetes, mean (SD)No diabetes, mean (SD)Difference, mean (SE)&
AIR1.04 (0.17)0.98 (0.16)0.062 (0.046)0.006 (0.062)0.014 (0.042)−0.008 (0.013)
ARIC0.83 (0.16)0.76 (0.13)0.054 (0.004)0.015 (0.055)0.015 (0.044)0.000 (0.002)
BHS0.91 (0.22)0.75 (0.12)0.092 (0.019)−0.006 (0.102)0.001 (0.048)−0.009 (0.008)
Bruneck1.02 (0.15)0.95 (0.18)0.004 (0.022)0.022 (0.032)0.028 (0.027)−0.004 (0.004)
CCCC0.79 (0.20)0.73 (0.18)0.032 (0.015)0.023 (0.048)0.019 (0.049)0.004 (0.004)
CHS11.09 (0.20)1.03 (0.18)0.050 (0.007)0.013 (0.070)0.009 (0.060)0.004 (0.002)
CHS21.11 (0.18)1.09 (0.19)0.020 (0.024)−0.006 (0.035)0.004 (0.035)−0.010 (0.005)
CMCS0.92 (0.29)0.88 (0.25)0.043 (0.034)0.051 (0.053)0.053 (0.057)−0.002 (0.008)
DIWA1.07 (0.23)0.98 (0.18)0.088 (0.030)0.001 (0.026)0.008 (0.026)−0.007 (0.004)
KIHD1.08 (0.17)1.06 (0.22)0.004 (0.038)0.063 (0.041)0.066 (0.049)−0.002 (0.009)
NOMAS/INVEST0.93 (0.09)0.94 (0.09)−0.002 (0.001)0.008 (0.029)0.009 (0.032)−0.002 (0.003)
PIVUS1.12 (0.17)1.06 (0.17)0.056 (0.025)0.020 (0.043)0.015 (0.036)0.005 (0.005)
PLIC0.82 (0.13)0.73 (0.15)0.032 (0.015)0.003 (0.038)0.009 (0.043)−0.006 (0.005)
Rotterdam1.08 (0.17)1.01 (0.16)0.047 (0.013)0.012 (0.020)0.016 (0.023)−0.004 (0.002)
SHIP0.98 (0.20)0.89 (0.19)0.036 (0.011)0.002 (0.032)0.000 (0.031)0.001 (0.002)
Tromsø1.09 (0.21)0.97 (0.18)0.082 (0.017)0.014 (0.043)0.005 (0.025)0.009 (0.003)
Combined (CI 95%)*0.96 (0.22)0.87 (0.20)0.046 (0.041–0.051)0.013 (0.055)0.015 (0.043)−0.000 (−0.002 to 0.001)
  • Max CCA-IMT is not available in CAPS, Edinburgh Artery Study (EAS), Estudio epidemiológico sobre enfermedades y factores de riesgo cardiovasculares en ancianos españoles (EPICARDIAN), INVADE, and Salzburg Atherosclerosis Prevention program in subjects at High Individual Risk (SAPHIR). AIR, Atherosclerosis and Insulin Resistance study; CCCC, Chin-Shan Community Cardiovascular Cohort; CMCS, Chinese Multi-provincial Cohort Study; DIWA, Diabetes, Impaired glucose tolerance in Women and Atherosclerosis; KIHD, Kuopio Ischaemic Heart Disease study; PIVUS, Prospective Investigation of the Vasculature in Uppsala Seniors; PLIC, Progression of Lesions in the Intima of the Carotid; Rotterdam, Rotterdam Study; Tromsø, Tromsø Study.

  • &Adjusted for age and sex by multiple regression.

  • *Combined means and SDs weighted by sample size; differences between people with and without diabetes combined by random-effects meta-analysis.